GLP-1 receptors agonization as an effective antiatherosclerotic strategy
Authors:
Michal Vrablík
Authors‘ workplace:
Centrum preventivní kardiologie, III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in:
AtheroRev 2025; 10(1): 30-32
Category:
Reviews
Overview
The SELECT and SOUL studies evaluated the effectiveness of semaglutide in the prevention of cardiovascular complications in patients with overweight, obesity and type 2 diabetes. SELECT study confirmed that weekly subcutaneous semaglutide reduced cardiovascular risk in overweight/preobesity non-diabetic patients, leading to weight loss, reductions in blood pressure and inflammatory markers. SOUL study investigated the effects of oral semaglutide in patients with type 2 diabetes with ACS or CKD and showed a 14% reduction in cardiovascular mortality, heart attack and stroke compared to placebo. The results confirm that semaglutide represents a significant benefit in cardiovascular prevention.
Keywords:
overweight – type 2 diabetes mellitus – cardiovascular risk – cardiovascular prevention – (pre)obesity – SELECT study semaglutide (subcutanneous/oral) – SOUL study
Sources
Ryan DH, Lingvay I, Colhoun HM et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61–69. Dostupné z DOI: <https://doi: 10.1016/j.ahj.2020.07.008>. PMID: 32916609.
Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389(24): 2221–2232. Dostupné z DOI: <https://doi: 10.1056/NEJMoa2307563>.
Novo Nordisk A/S. Company announcement: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. Dostupné z WWW: <https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id= 166301>.
McGuire DK, Busui RP, Deanfield J et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab 2023; 25(7): 1932–1941. Dostupné z DOI: <https://doi: 10.1111/dom.15058>. PMID: 36945734.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2025 Issue 1
Most read in this issue
- Targeting lipoprotein(a): modification of cardiovascular risk and current treatment options
- SAA Consensus Statement EAS 2021: Triglyceride-rich lipoproteins and their remnant particles – a review of metabolism, role in atherosclerotic cardiovascular disease, and new therapeutic strategies
- Cardiovascular risk in obese individuals: how to keep it under control?
- The use of fenofibrate in the prevention of diabetic retinopathy progression: an interdisciplinary consensus